Industry News (Drug Resistance)

Joint Effort Researches HIV Drug Resistant Strains

Published in AIDS Weekly, October 25th, 1999

Hemispherx Biopharma, Inc., Pittsburgh, Pennsylvania, announced that it was developing clinical programs with Anderson Clinical Research that are designed to address the growing problem of multi-drug resistance found in battling the AIDS epidemic worldwide.

The programs will include the use of Ampligen, Hemispherx's lead compound, which is currently undergoing clinical trials in chronic viral infections.

"We are very excited about the prospects for Ampligen to fill a major void in our overall therapeutic approach to HIV. This excitement is based on our experience, not only with Ampligen, but other promising immunotherapeutics - regrettably of which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry